FKB 01MD

Drug Profile

FKB 01MD

Alternative Names: FKB01MD; TGBA 01AD

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antidepressants
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1D receptor modulators; Serotonin 2 receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 15 Mar 2017 TGBA01AD is available for licensing. http://www.fabrekramer.com
  • 08 Jan 2016 Phase-II development for Major depressive disorder is ongoing in USA
  • 16 Nov 2011 TGBA01AD is available for licensing. http://www.fabrekramer.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top